enGene (ENGN) – Analysts’ Weekly Ratings Updates
by Renee Jackson · The Cerbat GemenGene (NASDAQ: ENGN) has recently received a number of price target changes and ratings updates:
- 5/14/2026 – enGene had its price target lowered by UBS Group AG from $9.00 to $2.00. They now have a “neutral” rating on the stock.
- 5/8/2026 – enGene was downgraded by Raymond James Financial, Inc. from “strong-buy” to “outperform”. They now have a $4.00 price target on the stock.
- 5/8/2026 – enGene was downgraded by Piper Sandler from “overweight” to “neutral”. They now have a $4.00 price target on the stock, down from $7.00.
- 5/8/2026 – enGene was downgraded by Citigroup Inc. from “market outperform” to “market perform”.
- 5/8/2026 – enGene had its “equal weight” rating reaffirmed by Wells Fargo & Company. They now have a $2.00 price target on the stock, down from $25.00.
- 5/8/2026 – enGene was downgraded by Wells Fargo & Company from “overweight” to “equal weight”. They now have a $2.00 price target on the stock.
- 5/8/2026 – enGene was downgraded by Citizens Jmp from “outperform” to “market perform”.
- 5/8/2026 – enGene was downgraded by Leerink Partners from “outperform” to “market perform”. They now have a $2.00 price target on the stock.
- 5/8/2026 – enGene was downgraded by Morgan Stanley from “overweight” to “equal weight”.
- 5/8/2026 – enGene was downgraded by Oppenheimer Holdings, Inc. from “outperform” to “market perform”.
- 5/8/2026 – enGene had its price target lowered by HC Wainwright from $25.00 to $6.00. They now have a “buy” rating on the stock.
- 5/7/2026 – enGene was downgraded by Guggenheim from “buy” to “neutral”.
- 4/18/2026 – enGene was downgraded by Wall Street Zen from “hold” to “sell”.
- 4/13/2026 – enGene is now covered by WBB Securities. They set a “buy” rating and a $21.50 price target on the stock.
- 4/8/2026 – enGene had its “sell (d-)” rating reaffirmed by Weiss Ratings.
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.